300723 一品红
交易中 09-10 10:43:54
资讯
新帖
简况
9月4日一品红跌7.58%，易方达医疗保健行业混合A基金重仓该股
证券之星 · 09-04
9月4日一品红跌7.58%，易方达医疗保健行业混合A基金重仓该股
一品红最新公告：全资子公司获得注射用硫酸艾沙康唑注册证书
证券之星 · 09-01
一品红最新公告：全资子公司获得注射用硫酸艾沙康唑注册证书
9月1日一品红涨10.91%，易方达医疗保健行业混合A基金重仓该股
证券之星 · 09-01
9月1日一品红涨10.91%，易方达医疗保健行业混合A基金重仓该股
一品红最新公告：全资子公司获得草酸艾司西酞普兰滴剂注册证书
证券之星 · 08-25
一品红最新公告：全资子公司获得草酸艾司西酞普兰滴剂注册证书
一品红（300723）2025年中报简析：净利润同比下降258.3%，三费占比上升明显
证券之星 · 08-22
一品红（300723）2025年中报简析：净利润同比下降258.3%，三费占比上升明显
股市必读：一品红中报 - 第二季度单季净利润同比下降140.74%
证券之星 · 08-21
股市必读：一品红中报 - 第二季度单季净利润同比下降140.74%
一品红上半年净利润亏损7354.22万元 同比由盈转亏
北京商报 · 08-21
一品红上半年净利润亏损7354.22万元 同比由盈转亏
图解一品红中报：第二季度单季净利润同比下降140.74%
证券之星 · 08-21
图解一品红中报：第二季度单季净利润同比下降140.74%
一品红最新公告：痛风创新药AR882全球Ⅲ期临床试验完成全部受试者入组
证券之星 · 08-21
一品红最新公告：痛风创新药AR882全球Ⅲ期临床试验完成全部受试者入组
一品红公布半年报 上半年净利减少258.3%
新浪财经-鹰眼工作室 · 08-21
一品红公布半年报 上半年净利减少258.3%
一品红(300723.SZ)发布上半年业绩，由盈转亏至7354.22万元
智通财经 · 08-21
一品红(300723.SZ)发布上半年业绩，由盈转亏至7354.22万元
一品红：2025年上半年净利润亏损7354.22万元
格隆汇 · 08-21
一品红：2025年上半年净利润亏损7354.22万元
一品红：AR882全球Ⅲ期试验入组过半
证券之星 · 08-19
一品红：AR882全球Ⅲ期试验入组过半
8月13日一品红涨6.81%，易方达医疗保健行业混合A基金重仓该股
证券之星 · 08-13
8月13日一品红涨6.81%，易方达医疗保健行业混合A基金重仓该股
一品红(300723.SZ)子公司创新药APH03621片获得临床试验注册申请受理
智通财经 · 08-04
一品红(300723.SZ)子公司创新药APH03621片获得临床试验注册申请受理
7月31日一品红涨5.42%，易方达医疗保健行业混合A基金重仓该股
证券之星 · 07-31
7月31日一品红涨5.42%，易方达医疗保健行业混合A基金重仓该股
一品红(300723.SZ)子公司获得复方聚乙二醇电解质散(Ⅲ)注册证书
智通财经 · 07-31
一品红(300723.SZ)子公司获得复方聚乙二醇电解质散(Ⅲ)注册证书
一品红(300723.SZ)子公司获得西咪替丁注射液注册证书
智通财经 · 07-31
一品红(300723.SZ)子公司获得西咪替丁注射液注册证书
生物疫苗概念盘中拉升，一品红涨4.45%
市场透视 · 07-28
生物疫苗概念盘中拉升，一品红涨4.45%
7月24日一品红跌6.46%，易方达医疗保健行业混合A基金重仓该股
证券之星 · 07-24
7月24日一品红跌6.46%，易方达医疗保健行业混合A基金重仓该股
加载更多
公司概况
公司名称：
一品红药业集团股份有限公司
所属行业：
医药制造业
上市日期：
2017-11-16
主营业务：
一品红药业集团股份有限公司的主营业务是药品的研发、生产和销售。公司的主要产品是化学药(含原料药和制剂)、特色中成药等。公司曾先后获得中国化药研发综合实力百强企业、中国创新力医药企业100强和中国化药企业百强企业等荣誉称号，是广州生物医药产业链的链主企业。
发行价格：
17.05
{"stockData":{"symbol":"300723","market":"SZ","secType":"STK","nameCN":"一品红","latestPrice":58.77,"timestamp":1757472234000,"preClose":68.56,"halted":0,"volume":13302922,"delay":0,"changeRate":-0.1428,"floatShares":418000000,"shares":451999999,"eps":-1.4613,"marketStatus":"交易中","change":-9.79,"latestTime":"09-10 10:43:54","open":67.11,"high":69.28,"low":58.58,"amount":839000000,"amplitude":0.1561,"askPrice":58.78,"askSize":7,"bidPrice":58.61,"bidSize":66,"shortable":0,"etf":0,"ttmEps":-1.4613,"tradingStatus":2,"nextMarketStatus":{"tag":"午间休市","tradingStatus":4,"beginTime":1757475000000},"marketStatusCode":2,"adr":0,"adjPreClose":68.56,"symbolType":"stock","openAndCloseTimeList":[[1757467800000,1757475000000],[1757480400000,1757487600000]],"highLimit":75.42,"lowLimit":61.7,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":451692766,"isCdr":false,"pbRate":17.08,"roa":"--","roe":"--","epsLYR":-1.1956,"committee":-0.477833,"marketValue":26546000000,"turnoverRate":0.0319,"status":1,"floatMarketCap":24546000000},"requestUrl":"/m/hq/s/300723","defaultTab":"news","newsList":[{"id":"2564322486","title":"9月4日一品红跌7.58%，易方达医疗保健行业混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2564322486","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2564322486?lang=zh_cn&edition=full","pubTime":"2025-09-04 16:35","pubTimestamp":1756974959,"startTime":"0","endTime":"0","summary":"证券之星消息，9月4日一品红跌7.58%，收盘报67.27元，换手率2.99%，成交量12.48万手，成交额8.78亿元。重仓一品红的前十大公募基金请见下表：该股最近90天内共有3家机构给出评级，买入评级2家，增持评级1家。根据2025基金半年报公募基金重仓股数据，重仓该股的公募基金共61家，其中持有数量最多的公募基金为易方达基金的易方达医疗保健行业混合A。易方达医疗保健行业混合A目前规模为39.44亿元，最新净值4.877，较上一交易日上涨2.09%，近一年上涨68.35%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025090400025481.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300723"],"gpt_icon":0},{"id":"2564815678","title":"一品红最新公告：全资子公司获得注射用硫酸艾沙康唑注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2564815678","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2564815678?lang=zh_cn&edition=full","pubTime":"2025-09-01 17:50","pubTimestamp":1756720229,"startTime":"0","endTime":"0","summary":"一品红(300723.SZ)公告称，公司全资子公司广州一品红制药有限公司收到国家药品监督管理局核准签发的注射用硫酸艾沙康唑的《药品注册证书》。该药品主要用于治疗成人患者的侵袭性曲霉病和侵袭性毛霉病，属于化学药品4类，视同通过一致性评价。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025090100024797.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300723"],"gpt_icon":0},{"id":"2564890534","title":"9月1日一品红涨10.91%，易方达医疗保健行业混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2564890534","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2564890534?lang=zh_cn&edition=full","pubTime":"2025-09-01 16:29","pubTimestamp":1756715382,"startTime":"0","endTime":"0","summary":"证券之星消息，9月1日一品红涨10.91%，收盘报73.63元，换手率4.28%，成交量17.86万手，成交额12.82亿元。重仓一品红的前十大公募基金请见下表：该股最近90天内共有3家机构给出评级，买入评级2家，增持评级1家。根据2025基金半年报公募基金重仓股数据，重仓该股的公募基金共61家，其中持有数量最多的公募基金为易方达基金的易方达医疗保健行业混合A。易方达医疗保健行业混合A目前规模为39.44亿元，最新净值4.684，较上一交易日上涨2.7%，近一年上涨61.35%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025090100021312.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300723","BK0239"],"gpt_icon":0},{"id":"2562248949","title":"一品红最新公告：全资子公司获得草酸艾司西酞普兰滴剂注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2562248949","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2562248949?lang=zh_cn&edition=full","pubTime":"2025-08-25 18:20","pubTimestamp":1756117224,"startTime":"0","endTime":"0","summary":"一品红(300723.SZ)公告称，公司全资子公司广州一品红制药有限公司近日收到国家药品监督管理局核准签发的草酸艾司西酞普兰滴剂的《药品注册证书》。该药品适应症为治疗抑郁症和伴有或不伴有广场恐怖症的惊恐障碍。此次获得注册证书，标志着公司具备了在国内市场销售该药品的资格，将进一步丰富公司产品管线和产品品类，增强公司在慢病药领域的竞争力。但需注意医药产品存在销售不达预期的风险。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025082500025784.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300723","BK0239"],"gpt_icon":0},{"id":"2561285435","title":"一品红（300723）2025年中报简析：净利润同比下降258.3%，三费占比上升明显","url":"https://stock-news.laohu8.com/highlight/detail?id=2561285435","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2561285435?lang=zh_cn&edition=full","pubTime":"2025-08-23 06:17","pubTimestamp":1755901079,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期一品红发布2025年中报。截至本报告期末，公司营业总收入5.84亿元，同比下降36.02%，归母净利润-7354.22万元，同比下降258.3%。按单季度数据看，第二季度营业总收入2.07亿元，同比下降28.59%，第二季度归母净利润-1.3亿元，同比下降140.74%。本报告期一品红三费占比上升明显，财务费用、销售费用和管理费用总和占总营收同比增幅达37.93%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025082300006714.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300723"],"gpt_icon":0},{"id":"2561908024","title":"股市必读：一品红中报 - 第二季度单季净利润同比下降140.74%","url":"https://stock-news.laohu8.com/highlight/detail?id=2561908024","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2561908024?lang=zh_cn&edition=full","pubTime":"2025-08-22 01:19","pubTimestamp":1755796748,"startTime":"0","endTime":"0","summary":"业绩披露要点：一品红2025年中报显示，公司主营收入5.84亿元，同比下降36.02%，归母净利润亏损7354.22万元，同比下降258.3%。股本股东变化近日一品红披露，截至2025年7月31日公司股东户数为2.13万户，较6月30日增加4144户，增幅为24.22%。其中2025年第二季度，公司单季度主营收入2.07亿元，同比下降28.59%；单季度归母净利润-1.3亿元，同比下降140.74%；单季度扣非净利润-1.23亿元，同比下降95.46%；负债率62.53%，投资收益948.57万元，财务费用2724.71万元，毛利率58.28%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025082200001575.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300723"],"gpt_icon":0},{"id":"2561949549","title":"一品红上半年净利润亏损7354.22万元 同比由盈转亏","url":"https://stock-news.laohu8.com/highlight/detail?id=2561949549","media":"北京商报","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2561949549?lang=zh_cn&edition=full","pubTime":"2025-08-21 21:09","pubTimestamp":1755781740,"startTime":"0","endTime":"0","summary":"8月21日晚间，一品红（300723）披露2025年半年报显示，公司上半年实现营业收入5.84亿元，同比下降36.02%；归属净利润为-7354.22万元，同比由盈转亏。 针对营收下滑的原因，一品红表示，主要是受市场环境变化影响销售不及预期所致。（文章来源：北京商报）\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2025-08-21/doc-infmuhuz7673975.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2025-08-21/doc-infmuhuz7673975.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["300723"],"gpt_icon":0},{"id":"2561771463","title":"图解一品红中报：第二季度单季净利润同比下降140.74%","url":"https://stock-news.laohu8.com/highlight/detail?id=2561771463","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2561771463?lang=zh_cn&edition=full","pubTime":"2025-08-21 17:41","pubTimestamp":1755769260,"startTime":"0","endTime":"0","summary":"证券之星消息，一品红2025年中报显示，公司主营收入5.84亿元，同比下降36.02%；归母净利润-7354.22万元，同比下降258.3%；扣非净利润-1.08亿元，同比下降410.19%；其中2025年第二季度，公司单季度主营收入2.07亿元，同比下降28.59%；单季度归母净利润-1.3亿元，同比下降140.74%；单季度扣非净利润-1.23亿元，同比下降95.46%；负债率62.53%，投资收益948.57万元，财务费用2724.71万元，毛利率58.28%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025082100030060.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300723"],"gpt_icon":0},{"id":"2561468714","title":"一品红最新公告：痛风创新药AR882全球Ⅲ期临床试验完成全部受试者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2561468714","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2561468714?lang=zh_cn&edition=full","pubTime":"2025-08-21 17:19","pubTimestamp":1755767987,"startTime":"0","endTime":"0","summary":"一品红(300723.SZ)公告称，公司参股公司Arthrosi Therapeutics,Inc.组织的AR882全球关键性Ⅲ期临床试验已完成全部受试者入组。AR882是公司与美国Arthrosi合作研发的1类创新药，用于治疗痛风和痛风石。该试验是一项为期12个月的随机、双盲、安慰剂对照研究，旨在评估AR882的疗效。AR882全球Ⅲ期临床试验进展不会对公司近期业绩产生重大影响。药品从审批上市到实现销售周期长，上市后能否被市场接纳和应用也具有不确定性。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025082100029411.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["06978","159992","300723","BK0239","BK1574","BK1161"],"gpt_icon":0},{"id":"2561450931","title":"一品红公布半年报 上半年净利减少258.3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2561450931","media":"新浪财经-鹰眼工作室","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2561450931?lang=zh_cn&edition=full","pubTime":"2025-08-21 16:40","pubTimestamp":1755765600,"startTime":"0","endTime":"0","summary":"炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 8月21日消息，一品红发布半年度报告。 公告显示，公司半年度营业收入583,798,099.16元，同比减少36.02%，归属上市公司股东的净利润-73,542,195.36元，同比减少258.3%。 公告显示，十大流通股东中，中国银行股份有限公司－易方达医疗保健行业混合型证券投资基金、富国基金－中国人寿保险股份有限公司－传统险－富国基金国寿股份成长股票传统可供出售单一资产管理计划为新进流通股东。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：小浪快报","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/ggzz/2025-08-21/doc-infmtrxi7943496.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0239","300723"],"gpt_icon":0},{"id":"2561452480","title":"一品红(300723.SZ)发布上半年业绩，由盈转亏至7354.22万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2561452480","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2561452480?lang=zh_cn&edition=full","pubTime":"2025-08-21 16:12","pubTimestamp":1755763958,"startTime":"0","endTime":"0","summary":"智通财经APP讯，一品红(300723.SZ)发布2025年半年度报告，该公司营业收入为5.84亿元，同比减少36.02%。归属于上市公司股东的净亏损为7354.22万元。归属于上市公司股东的扣除非经常性损益的净亏损为1.08亿元。基本每股亏损为0.1628元。2025上半年公司自主研发投入约9,420.10万元，占公司营业收入的16.14%。2025年至今公司新增产品注册批件10个。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1332738.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"一品红(300723.SZ)发布上半年业绩，由盈转亏至7354.22万元","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300723","BK0239"],"gpt_icon":0},{"id":"2561547964","title":"一品红：2025年上半年净利润亏损7354.22万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2561547964","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2561547964?lang=zh_cn&edition=full","pubTime":"2025-08-21 15:55","pubTimestamp":1755762959,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK0239","300723"],"gpt_icon":0},{"id":"2560964169","title":"一品红：AR882全球Ⅲ期试验入组过半","url":"https://stock-news.laohu8.com/highlight/detail?id=2560964169","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2560964169?lang=zh_cn&edition=full","pubTime":"2025-08-19 16:24","pubTimestamp":1755591859,"startTime":"0","endTime":"0","summary":"证券之星消息，一品红08月19日在投资者关系平台上答复投资者关心的问题。截止2025年6月底，AR882全球关键性Ⅲ期REDUCE 1试验已完成超过50%的患者入组。截至8月1日，AR882国内Ⅲ期临床试验已入组超过50%的受试者，标志着该药全球同步研发的进程取得了又一重大进展。药品研发具有周期长、投入高、风险大等特点，敬请广大投资者谨慎决策，注意投资风险。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025081900027451.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300723","BK0239"],"gpt_icon":0},{"id":"2559220670","title":"8月13日一品红涨6.81%，易方达医疗保健行业混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2559220670","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2559220670?lang=zh_cn&edition=full","pubTime":"2025-08-13 16:24","pubTimestamp":1755073476,"startTime":"0","endTime":"0","summary":"证券之星消息，8月13日一品红涨6.81%，收盘报70.72元，换手率4.02%，成交量16.78万手，成交额11.65亿元。重仓一品红的前十大公募基金请见下表：该股最近90天内共有5家机构给出评级，买入评级4家，增持评级1家。根据2025基金半年报公募基金重仓股数据，重仓该股的公募基金共61家，其中持有数量最多的公募基金为易方达基金的易方达医疗保健行业混合A。易方达医疗保健行业混合A目前规模为39.44亿元，最新净值4.553，较上一交易日下跌1.73%，近一年上涨52.07%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025081300025722.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300723"],"gpt_icon":0},{"id":"2556480601","title":"一品红(300723.SZ)子公司创新药APH03621片获得临床试验注册申请受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2556480601","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2556480601?lang=zh_cn&edition=full","pubTime":"2025-08-04 16:04","pubTimestamp":1754294688,"startTime":"0","endTime":"0","summary":"智通财经APP讯，一品红(300723.SZ)发布公告，近日，公司全资子公司广州一品红制药有限公司自主研发的创新药物APH03621片的药物临床试验申请获得国家药品监督管理局受理，并收到《受理通知书》。APH03621是公司研制的一种新型口服、非肽类小分子促性腺激素释放激素受体拮抗剂(GnRH-ant)，拟用于子宫内膜异位症(简称“内异症”)治疗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1325324.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["159992","BK1161","BK0239","BK1574","300723","06978"],"gpt_icon":0},{"id":"2555900758","title":"7月31日一品红涨5.42%，易方达医疗保健行业混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2555900758","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2555900758?lang=zh_cn&edition=full","pubTime":"2025-07-31 16:18","pubTimestamp":1753949927,"startTime":"0","endTime":"0","summary":"证券之星消息，7月31日一品红涨5.42%，收盘报77.56元，换手率3.64%，成交量15.18万手，成交额11.69亿元。重仓一品红的前十大公募基金请见下表：该股最近90天内共有6家机构给出评级，买入评级5家，增持评级1家。根据2025基金半年报公募基金重仓股数据，重仓该股的公募基金共61家，其中持有数量最多的公募基金为易方达基金的易方达医疗保健行业混合A。易方达医疗保健行业混合A目前规模为39.44亿元，最新净值4.594，较上一交易日下跌1.88%，近一年上涨62.5%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025073100025279.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300723","BK0239"],"gpt_icon":0},{"id":"2555077807","title":"一品红(300723.SZ)子公司获得复方聚乙二醇电解质散(Ⅲ)注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2555077807","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2555077807?lang=zh_cn&edition=full","pubTime":"2025-07-31 11:55","pubTimestamp":1753934113,"startTime":"0","endTime":"0","summary":"智通财经APP讯，一品红(300723.SZ)发布公告，公司全资子公司广州一品红制药有限公司于近日收到国家药品监督管理局核准签发的关于复方聚乙二醇电解质散(Ⅲ)的《药品注册证书》，复方聚乙二醇电解质散(Ⅲ)适应症为：用于以下情况之前的患者结肠清洁准备：--内窥镜或放射检查--结肠手术，本品适用于成人。此次公司获得复方聚乙二醇电解质散(Ⅲ)注册证书，标志着公司具备了在国内市场销售该规格药品的资格，将进一步丰富公司产品管线和产品品类，增强了公司的核心竞争力。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1324010.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"一品红(300723.SZ)子公司获得复方聚乙二醇电解质散(Ⅲ)注册证书","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","300723"],"gpt_icon":0},{"id":"2555077827","title":"一品红(300723.SZ)子公司获得西咪替丁注射液注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2555077827","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2555077827?lang=zh_cn&edition=full","pubTime":"2025-07-31 11:53","pubTimestamp":1753934006,"startTime":"0","endTime":"0","summary":"智通财经APP讯，一品红(300723.SZ)发布公告，公司全资子公司广州市联瑞制药有限公司于近日收到国家药品监督管理局核准签发的关于西咪替丁注射液的《药品注册证书》，西咪替丁注射液适应症为：用于消化道溃疡。此次公司获得西咪替丁注射液注册证书，标志着公司具备了在国内市场销售该规格药品的资格，将进一步丰富公司产品管线和产品品类，增强了公司在慢病药领域的竞争力。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1324008.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","300723"],"gpt_icon":0},{"id":"2554741734","title":"生物疫苗概念盘中拉升，一品红涨4.45%","url":"https://stock-news.laohu8.com/highlight/detail?id=2554741734","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2554741734?lang=zh_cn&edition=full","pubTime":"2025-07-28 09:36","pubTimestamp":1753666598,"startTime":"0","endTime":"0","summary":"07月28日，生物疫苗概念盘中拉升，截至09点36分，生物疫苗概念整体指数上涨0.52%，报2475.810点。从个股上来看，该概念的成分股中，一品红涨4.45%，生物股份、科前生物、健康元涨幅居前。从资金上来看，截止发稿，生物疫苗概念主力净流入为-3061.63万，其中塞力医疗受到资金热捧，主力净流入1505.21万；拉长时间线来看，该板块近20日主力资金净流入-27.12亿。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250728093638a6c4dce2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250728093638a6c4dce2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["600380","BK0077","BK0188","BK0239","BK0028","600201","603716","159657","688526","BK0046","BK0185","BK0196","BK0012","300723"],"gpt_icon":0},{"id":"2553270894","title":"7月24日一品红跌6.46%，易方达医疗保健行业混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2553270894","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2553270894?lang=zh_cn&edition=full","pubTime":"2025-07-24 16:28","pubTimestamp":1753345725,"startTime":"0","endTime":"0","summary":"证券之星消息，7月24日一品红跌6.46%，收盘报75.11元，换手率3.92%，成交量16.36万手，成交额12.33亿元。根据2025基金半年报公募基金重仓股数据，重仓该股的公募基金共61家，其中持有数量最多的公募基金为易方达基金的易方达医疗保健行业混合A。易方达医疗保健行业混合A目前规模为39.44亿元，最新净值4.491，较上一交易日下跌0.97%，近一年上涨51.93%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025072400025021.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300723"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1757472238582,"stockEarnings":[{"period":"1week","weight":-0.0459},{"period":"1month","weight":0.0081},{"period":"3month","weight":0.167},{"period":"6month","weight":1.877},{"period":"1year","weight":3.8384},{"period":"ytd","weight":3.0188}],"compareEarnings":[{"period":"1week","weight":-0.0132},{"period":"1month","weight":0.0474},{"period":"3month","weight":0.119},{"period":"6month","weight":0.1336},{"period":"1year","weight":0.3913},{"period":"ytd","weight":0.1359}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"一品红药业集团股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"21255人(较上一季度增加24.22%)","perCapita":"19650股","listingDate":"2017-11-16","address":"广东省广州市黄埔区广州国际生物岛寰宇一路27号云润大厦17层","registeredCapital":"45169万元","survey":" 一品红药业集团股份有限公司的主营业务是药品的研发、生产和销售。公司的主要产品是化学药(含原料药和制剂)、特色中成药等。公司曾先后获得中国化药研发综合实力百强企业、中国创新力医药企业100强和中国化药企业百强企业等荣誉称号，是广州生物医药产业链的链主企业。","listedPrice":17.05},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.34.9","shortVersion":"4.34.9","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"一品红(300723)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供一品红(300723)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"一品红,300723,一品红股票,一品红股票老虎,一品红股票老虎国际,一品红行情,一品红股票行情,一品红股价,一品红股市,一品红股票价格,一品红股票交易,一品红股票购买,一品红股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"一品红(300723)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供一品红(300723)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}